INSURANCE COMPANIES

Medicina genómica para compañias aseguradoras

INSURANCE COMPANIES

Genomic medicine and microbiome analysis are redefining prevention, diagnosis, and the personalization of treatments in clinical practice. In this context, insurance companies have the opportunity to incorporate innovative solutions that provide clinical value, healthcare efficiency, and meaningful differentiation within their service portfolio.

In Spain, the National Health System has progressed in updating the catalog of genetic tests included in the common service portfolio, incorporating pharmacogenomic analyses for certain treatments as part of the implementation of precision personalized medicine. This context raises the standard of care and reinforces the opportunity for insurers to update their coverage with services aligned with current clinical practice.

Together for more precise medicine

INSURANCE COMPANIES

Integration of clinical genomics

At Eugenomic, we help insurance companies integrate genomic medicine in a practical and scalable way to strengthen three key objectives:

🔹 Real portfolio differentiation
Incorporating clinical genomics and pharmacogenetics solutions makes it possible to offer advanced services aligned with personalized medicine, reinforcing the insurer’s innovative positioning and delivering tangible clinical value to its medical network.

🔹 Improved risk and healthcare cost management
Genetic information is a key foundation of predictive medicine, supporting clinical decision-making in complex patients and optimizing the use of healthcare resources.

🔹 Greater member loyalty and value
Genomic medicine analyses are perceived as personalized and distinctive, enhancing the member experience and strengthening their relationship with the insurer.

Eugenomic - medicina genómica para compañías aseguradoras

Eugenomic solutions for insurance companies

Portfolio of products and services

Eugenomic offers a portfolio of solutions focused on prevention, risk stratification, and support for clinical decision-making, designed to be flexibly integrated into the service portfolio and adapted to different policy models (included service, co-payment, specific programs, or segmentation by risk profiles).

Preventive genomic medicine

Analyses that help identify relevant genetic predispositions and support personalized health programs. This approach makes it possible to understand susceptibility to certain conditions in order to deliver personalized preventive medicine.

Pharmacogenetics (PGx)

Analysis of genetic variants associated with drug response to support prescribing, contribute to treatment optimization, and help reduce potential risks in medication use, especially in polymedicated patients or those with greater clinical complexity.

Microbiota studies

Advanced analyses of the intestinal and vaginal microbiome aimed at assessing health status, supporting prevention, and personalizing clinical interventions, complementing genomic information with functional data relevant to digestive, metabolic, immune, and women’s health.

g-Nomic®

Pharmacogenetic interpretation and interactions: clinical interpretation software that supports healthcare professionals in optimizing treatments and reducing risks associated with medication use.

A model tailored to each client

Flexibility in incorporating services into the portfolio

Eugenomic’s solutions enable each insurance company to define its own portfolio of services, according to its product strategy, client segmentation, and healthcare objectives.

A model tailored to each client:

Eugenomic integrates into each company’s healthcare ecosystem, offering:

🔹 Comprehensive program management, from design to the final report.

🔹 Integration with in-house medical networks or external providers.

🔹 White-label or co-branding options.

🔹 Support materials for communication and service activation, aimed at healthcare professionals and insured members.

Soluciones eugenomic para compañías aseguradoras

Why Eugenomic

Because we combine science, operations, and clinical adoption so that genomics is not just “a product,” but an integrable and usable service:

01

CLINICAL APPROACH: Results designed to support decision-making and real-world care pathways.

02

SCALABILITY: Programs designed to grow across policies, segments, or medical networks.

03

END-TO-END IMPLEMENTATION: Design, operations, professional support, and service activation.

04

BRAND AND MODEL FLEXIBILITY: White-label/co-branding options and adaptation to each insurer’s strategy.

05

VALUE-DRIVEN APPROACH: Definition of key metrics and support in program evaluation.

CONTACT OUR EXPERTS

Regardless of the size of the insurance company, we offer solutions and services designed to adapt to the specific needs of its members.

Simply complete the form and our team will contact you as soon as possible. If you prefer, you can call us at (+34) 932 922 963 or email us at info@eugenomic.com.

For urgent inquiries, you can also reach us at +34 682 90 27 73.

By sending this form I declare to agree with the Terms and Conditions and the Privacy Policy.

Thanks for your query

Out team will get back to you as soon as possible.